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Mutation of the West Nile virus-like particle (WN VLP) prM protein (T20D, K31A, K31V, or K31T) results
in undetectable VLP secretion from transformed COS-1 cells. K31 mutants formed intracellular prM-E
heterodimers; however these proteins remained in the ER and ER–Golgi intermediary compartments of
transfected cells. The T20D mutation affected glycosylation, heterodimer formation, and WN VLP
secretion. When infectious viruses bearing the same mutations were used to infect COS-1 cells, K31
mutant viruses exhibited delayed growth and reduced infectivity compared to WT virus. Epitope maps
of WN VLP and WNV prM were also different. These results suggest that while mutations in the prM
protein can reduce or eliminate secretion of WN VLPs, they have less effect on virus. This difference
may be due to the quantity of prM in WN VLPs compared to WNV or to differences in maturation,
structure, and symmetry of these particles.
Published by Elsevier Inc.Introduction
West Nile virus (WNV) is an emerging global pathogen causing
WN fever and meningoencephalitis. Since its introduction into the
Western Hemisphere in 1999 it has spread throughout North
and Central America and the Caribbean and currently is the leading
cause of mosquito-borne human encephalitis in the region
(Mackenzie et al., 2004). WNV is a member of the family Flaviviridae,
genus Flavivirus. It is maintained in an enzootic cycle between
mosquitoes and birds with humans and other mammals as inci-
dental hosts (Mackenzie et al., 2004). Other medically important
ﬂaviviruses include Japanese encephalitis virus (JEV), tick-borne
encephalitis virus (TBEV), yellow fever virus, and the four serotypes
of dengue viruses (DENV).
WNV has a single-stranded, positive sense 11 kb RNA genome
that encodes 3 structural proteins at its 50-end. The envelope
(E) protein is the major virion glycoprotein responsible for virus
membrane attachment and fusion. The capsid (C) protein binds
the genomic RNA to form the nucleocapsid. The pre-membrane
(prM) protein is a chaperone that assists in the maturation of the
E protein, and occurs as a prM-E heterodimer. The prM-E hetero-
dimers form 60 trimeric spikes on the surface of the immature
DEN2 virion that measures 600 A˚ in diameter (Li et al., 2008). The
pr peptide is the amino terminal part of the prM protein that isInc.cleaved from prM during virion maturation by the host multi-
basic-recognition protease furin. The pr remains associated with
the virion to protect the fusion loop of the E protein from
premature fusion until reaching an extracellular neutral pH
environment. Once the virion reaches a neutral pH, the pr peptide
dissociates, resulting in the formation of a fusion-competent
particle (Yu et al., 2009). Since this cleavage by furin can be
inefﬁcient, and appears to be host-cell dependent, not all virions
released from cells contain mature M and in fact, there is likely
populations of virions containing M, prM or a mixture of prM and
M on the virion surface as demonstrated by cryo-electron micro-
scopy (Cherrier et al., 2009; Junjhon et al., 2010; Pokidysheva
et al., 2006; Zhang et al., 2003). The existence of prM in infectious
ﬂavivirus particles has also been established with experiments
measuring pH sensitivity, viral tropism and neutralization capa-
city of antibodies with less accessible sites on E when prM is
present (Davis et al., 2006; Guirakhoo et al., 1992; Nelson et al.,
2008).
The polyprotein encoded by the ﬂavivirus RNA genome is
translated in association with the rough endoplasmic reticulum
(ER). Several transmembrane domains of the polyprotein traverse
the ER membrane and co- and post-translational cleavages to
produce functional products are carried out by the host enzyme
signalase and the virally-encoded protease NS2B-3 (Lindenbach
and Rice, 2003). The viral structural proteins prM and E form
dimers on the ER membrane, producing an icosahedral scaffold
that may or may not enclose the viral RNA genome packaged
in the nucleocapsid (Konishi et al., 1992; Schalich et al., 1996).
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Fig. 1. Mutations in the prM protein reduce secretion of VLPs. COS-1 cells were
transfected with wild type (WT) and mutant pVAXWN plasmids. Cell culture
supernatant was harvested 2 (open bars) and 7 (cross-hatched bars) days post-
transfection, and prM and E proteins were detected by ELISA. Mean absorbance
values (7SE) were calculated from two independent experiments performed in
duplicate. Asterisks indicate statistically signiﬁcant differences compared to WT
plasmid using Dunnett’s method of multiple comparisons with an overall type I
error of 0.05. Control, non-transfected cell control.
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bud into the lumen of the ER and are transported through the
Golgi for further envelope protein modiﬁcation, including glyco-
sylation of the structural proteins and cleavage of the pr peptide
from the prM protein by host furin protease. Virus particles
contained in vesicles are released from the cell through the
exocytic pathway (Mackenzie and Westaway, 2001).
Recent studies have shown the importance of the prM protein
in the maturation and secretion of virions and VLPs. Tan et al.
(2009) showed that the highly conserved tyrosine at amino acid
(AA) residue 78 in the ectodomain of the prM protein of WNV is
essential for virus assembly and secretion from cells (Tan et al.,
2009). The H99 residue in the prM protein of JEV, positioned
opposite from hydrophobic surfaces on the E protein, was shown
to be critical in the formation of prM-E heterodimers. The
transition to neutral pH may change interactions between amino
acids at this prM-E interface, leading to release of pr and
formation of mature virions (Li et al., 2008). Yoshii et al. (2004)
found that mutating the prM P63 to a serine greatly reduced the
production of VLPs and virions of TBEV (Yoshii et al., 2004). This
AA lies in the pr region of the prM protein that is conserved in
ﬂaviviruses and was shown to be crucial in the formation of
prM-E heterodimers (Yoshii et al., 2012). The loss of the N-linked
glycosylation site in the pr portion of JEV prM protein results in a
20-fold decrease in infectious virion production and decreased
virulence in mice inoculated peripherally with mutant virus (Kim
et al., 2008).
In order to map the epitope binding of 3 fully human mono-
clonal antibodies (hMAbs), we made four mutations (T20D, K31A,
K31V, K31T) in the prM protein of the WN VLP that resulted in
failure to secrete VLP antigen from transfected cells (Calvert et al.,
2011). Although VLPs were not secreted as a result of these
mutations, prM antigen was detected in the transfected COS-1
cells. In this report we examine the effects of these prMmutations
on WN VLP assembly and secretion as well as on infectious virus
replication and protein expression.Results
Mutations in WNV prM protein affect secretion of VLP
Previously, we constructed WN VLP mutants to identify the
epitopes on the prM protein recognized by 3 virus-speciﬁc hMAbs
(Calvert et al., 2011). All three of the mutations made at K31 in
the prM protein (K31A, K31T, K31V) resulted in signiﬁcantly
reduced secretion of VLP. Another mutation, T20D had the same
effect on VLP secretion. These mutations occurred in AA residues
that are located on the surface-exposed face of pr and did not
appear to be involved in interactions with the E protein in prM-E
heterodimers or disulﬁde bonds in the prM protein (Li et al.,
2008).
To investigate the effects of these mutations on VLP secretion,
COS-1 cells were transfected with WT and mutant (T20D, K31A,
K31T, and K31V) pVAXWN plasmids, cell culture supernatant was
harvested on days 2 and 7 post-transfection, and detection of viral
proteins was performed by antigen-capture ELISA, using poly-
clonal rabbit serum to WNV prM and E proteins as capture
antibody and mouse hyperimmune ascitic ﬂuid (MHIAF) to
WNV as detector antibody. Transfected cells were incubated at
37 1C up to 7 days. Detection of secreted prM and E proteins was
reduced signiﬁcantly for all prM mutants at day 2 and day
7 compared to WT using Dunnett’s method of multiple compar-
isons with an overall type I error of 0.05 (Fig. 1). We also
conducted experiments in which cells were incubated for the
ﬁrst 6 h at 37 1C and then transferred to 28 1C for 7 days, andsimilar results as those shown above were obtained (data not
shown). These data indicate that K31 and to some extent T20 may
play important roles in WN VLP secretion.
Effect of mutations in VLP prM on prM-E heterodimerization
During ﬂavivirus assembly prM and E proteins form hetero-
dimers that interact with the nucleocapsid and bud through the
ER membrane to form immature virus particles. Co-expression of
prM with E is necessary for correct folding of the E protein;
however, prM is able to form its native structure in the absence of
E protein (Konishi and Mason, 1993; Lorenz et al., 2002). To
determine if the mutations in prM disrupted prM-E heterodimer-
ization during formation of VLPs, COS-1 cells transfected with WT
and prM mutant pVAXWN plasmids were lysed, prM and E
proteins were immunoprecipitated with either anti-E or anti-
prM MAb, and precipitated viral proteins were detected by
immunoblot (Fig. 2). When VLPs were immunoprecipitated with
the anti-prM hMAb 8G8, the E protein was co-precipitated and
detected in all cell lysates transfected with WT and mutant
plasmids. (Fig. 2B). Interestingly, prM protein from the T20D
mutant was detected as a doublet corresponding to the glycosy-
lated and non-glycosylated forms of the protein. When VLPs were
immunoprecipitated with the anti-E mMAb 3.91D, prM protein
was detected in co-precipitate from lysates of cells transfected
with WT and K31A, K31T and K31V mutant plasmids but
apparently not with T20D mutant plasmid. When the concentra-
tion of lysate from cells transfected with T20D pVAXWN plasmid
was increased 2-fold in the immunoprecipitation reaction a very
small amount of non-glycosylated prM was detected (Fig. 2B).
These results suggest that heterodimerization of the E and prM
protein is not affected by mutations at K31, but is affected by the
T20D mutation on the prM protein. The mutation at T20 permits
production of both glycosylated and non-glycosylated forms of
prM, and only the non-glycosylated form of the protein appears to
associate with the E protein.
To conﬁrm that the T20D mutation resulted in production of
both glycosylated and non-glycosylated forms of prM, and that
glycosylation of the E and prM proteins was not affected by the
K31 mutations, prM and E proteins were immunoprecipitated
from cell lysates and digested with the endoglycosidase, PNGaseF,
which cleaves all types of N-linked glycans. The migration
patterns of treated and non-treated samples were compared
(Fig. 3A). The E protein from WT and prM mutants was shown
to be glycosylated as indicated by an apparent shift in mobility
Fig. 2. Immunoprecipitation of prM and E proteins in COS-1 cells transfected with mutant VLP. COS-1 cells were transfected with WT and mutant pVAXWN plasmids. At 2
days post-transfection, cells were lysed. Whole cell lysates (A) and lysates immunoprecipitated with an anti-E mMAb (3.91D) or an anti-prM hMAb (8G8) (B) were
separated by SDS-PAGE on a reduced 4–12% Bis–Tris gel and transferred to nitrocellulose membranes. Proteins bands were detected using anti-E mMAb (3.67G) and anti-
prM rabbit polyclonal sera. Non-transfected COS-1 cell lysate was used as a control (C).
Fig. 3. Analysis of glycosylation of prM and E proteins in COS-1 cells transfected
with mutant pVAXWN plasmids. COS-1 cells were transfected with WT and
mutant pVAXWN plasmids. At 48 h post-transfection, cells were lysed. Lysates
were immunoprecipitated with an anti-prM hMAb (8G8). Immunoprecipitated
proteins were digested with (A) PNGaseF (Fþ) or without PNGaseF (F), and with
(B) EndoH (Hþ) or without EndoH (H). Proteins were separated by SDS-PAGE
on a reduced 4–12% Bis–Tris gel and transferred to nitrocellulose membranes.
Protein bands were detected using anti-E mMAb, 3.67G, and anti-prM rabbit
polyclonal sera.
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K31 mutant plasmids were also shown to be glycosylated as
indicated by a shift in mobility from 20 kDa to 17 kDa. PNGaseF
digestion also conﬁrmed that the prM doublet seen in the lysate
from cells expressing the T20D mutant was due to expression of
both glycosylated and non-glycosylated forms of the protein since
only the smaller band (17 kDa) was visible after digestion. To
determine the form of the carbohydrates on prM and E immuno-
precipitated proteins were digested with endoglycosidase H
(EndoH), an enzyme which cleaves the chitobiosyl unit of the
high mannose form of the carbohydrate on the glycoprotein.
Migration patterns of EndoH treated and untreated samples were
compared (Fig. 3B). The E and prM glycoproteins of WT and
mutants were shown to be sensitive to EndoH digestion indicat-
ing that in cells the glycoproteins were predominately in highmannose form. Processing of high mannose carbohydrates to the
complex form takes place in the Golgi, therefore, since these
protein still contained the high mannose form of the carbohydrate
they must localize to the ER. The overall decrease in prM and E
protein concentrations from T20D compared to WT may reﬂect
the inability of this construct to assemble heterodimers. Since the
K31 mutants expressed equal amounts of prM and E proteins in
transfected cells as WT, these contructs may be able to form
stable prM-E heterodimers but unable to form stable particles
that can interact with cellular factors for efﬁcient release
from cells.
Mutations in WNV prM protein affect cellular localization of viral
proteins
The immunoprecipitation results indicated that intracellular
prM-E heterodimers are formed with the K31 prM mutants and to
a much lesser extent with the T20D prM mutant, however, as
shown previously, the VLPs are not secreted. Therefore, the block
in secretion must occur in a later step in replication. During
assembly, ﬂaviviruses bud into the ER lumen of virus-infected
cells and are transported to the Golgi for subsequent processing
(Lindenbach and Rice, 2003). To determine whether the prM
mutations had an impact on the distrubution of viral proteins
inside the cell, COS-1 cells transfected with WT and prM mutant
pVAXWN plasmids were ﬁxed at 6, 12, 24 and 48 h post-
transfection, permeabilized and double stained with antibodies
to detect E protein (mMAb 3.91D), and either ER (anti-calreticu-
lin), coatomer (anti-bCOP I), ER-Golgi intermediate compartment
(anti-ERGIC53) or Golgi (anti-GRASP65) markers (Fig. 4). At 6 h E
protein expressed by WT and prM mutant plasmids coincided
with ER, and ERGIC markers, with some coincidence with bCOPI
and no coincidence with Golgi (data not shown). In WT trans-
fected cells at 12 h post-transfection the distribution of the E
protein completely coincided with the ER and ERGIC, and to some
extent with the Golgi (Fig. 4A). At 24 h post-transfection WT E
protein completely coincided with ER and ERGIC markers while
moderate coincidence of E protein with the Golgi marker was
observed (Fig. 4B). Staining of cells transfected with T20D mutant
had simliar staining to WT. At 12 h post-transfection distrubution
Fig. 4. Intracellular localization of expressed E proteins of COS-1 cells transfected with prM mutant pVAXWN plasmids. Transfected COS-1 cells expressing pVAXWN WT
and prM mutant plasmids were ﬁxed 12 (A) and 24 (B) hours post-transfection and stained with antibodies against WNV E protein (3.91D) and calreticulin, an ER marker,
ER–Golgi intermediary complexes bCOP1 and ERGIC53 or GRASP65, a Golgi marker. Co-localization of the E protein with these marker proteins are depicted in the merged
image. Nuclei of cells were stained with DAPI and shown in the merged image.
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markers, with moderate coincidence with Golgi marker; however,
unlike WT, T20D E protein also conincided with bCOPI marker
(Fig. 4A). At 24 h postransfection distribution of the E protein
expressed from the T20D mutant moderately coincided with ER
and ERGIC markers with less coincidence with bCOPI marker and
no coincidence with Golgi marker (Fig. 4B).
Distribution of the E protein expressed by the K31 mutants in
transfected cells appeared to be different from WT. Moderate
coincidence of E protein with bCOPI and Golgi markers and
complete coincidence with ER and ERGIC markers were observed
in cells transfected with K31 mutant plasmids at 12 h post-
transfection (Fig. 4A). At 24 h post-transfection the E protein
expressed by K31 mutants coincided with ER, ERGIC and some-
what with bCOPI markers. Staining of E protein expressed by K31
mutants and Golgi marker was not colocalized at 24 h (Fig. 4B). At
48 h E protein expressed by WT and prM mutant plasmids
coincided with ER, bCOPI, and ERGIC markers. Unlike WT which
did not co-localize with Golgi at 48 h, E protein expressed from
K31 mutants coincided somewhat with Golgi marker (data not
shown).
The most stricking result was the extremely concentrated and
localized distribution of the E protein in cells expressing
K31 mutants compared to the staining of the E protein from
cells transfected with WT plasmid. These observations suggest
that mutations at K31 in the prM protein result in an accumula-
tion of E protein in the ER, ER–Golgi intermediary compartments
and to some extent the Golgi complex, possibly due to the
inability of these mutant prM-E heterodimers to effectively
interact with unknown cellular factors in order to be secreted
from the cell.Effect of mutations in prM protein on virus replication
To determine if these prM VLP secretion-blocking mutations
had an effect on virus maturation and release, the same mutations
were introduced into an infectious cDNA clone of the WNV
genome. C6/36 cells were transfected with in vitro transcribed,
mutant WNV RNA and virus was harvested 7 days after transfec-
tion. Virus and viral RNA production were measured by plaque
assay and quantitative RT-PCR (qRT-PCR). The prM and E genes of
WT and mutant virus RNA were sequenced on day 0 and day 7,
and the introduced mutations were found to be present with no
compensatory mutations identiﬁed. Growth characteristics of
viruses were determined in one mosquito cell line (C6/36) and
two mammalian cell lines (Vero and COS-1) by infecting cells at a
multiplicity of infection (MOI) of 0.1 and analyzing daily medium
samples by plaque assay. All 4 prM mutant viruses grew similarly
to WT in C6/36 cells except for K31T, which had a titer 10-fold
lower than WT virus from day 1 to day 4 (Fig. 5A). The prM
mutant viruses also grew similarly to WT virus in Vero cells after
day 2; however, all mutant viruses grew more slowly than WT
between days 0 and 2 (Fig. 5B). Growth of the prM mutant viruses
as compared to WT were most different in COS-1 cells. While
K31V grew similarly to WT virus, T20D, K31A and K31T virus
titers were about 10-fold lower (Fig. 5C). Average plaque sizes in
Vero cells of prM mutant viruses harvested from these growth
studies were compared to WT virus. No signiﬁcant difference
between T20D and WT plaque sizes was seen in viruses grown in
any cell type. Average plaque sizes for K31A and K31T were
signiﬁcantly smaller compared to WT for viruses obtained from
all three cell lines. The average plaque sizes were signiﬁcantly less
only for the K31V mutant obtained from C6/36 cells (Table 1).
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Fig. 5. Virus growth kinetics in C636, Vero, and COS-1cells. C636 (A), Vero (B) or
COS-1 (C) cells were infected at a MOI of 0.1 and virus titers were measured by
plaque assay every day for 7 days. Bold line indicates assay limit of detection.
Standard error bars are shown for days 4 and 6. The data shown are from two
independent experiments.
Table 1
Average plaque sizes of WT and prM mutants viruses.
Cellsa Virus plaque size (mm)b
WT T20D K31A K31T K31V
C636 5.7571.0 5.3571.2 3.570.9*c 2.7570.7* 4.471.2*
Vero 5.671.6 5.271.2 3.170.8* 3.071.1* 4.1571.0*
COS-1 5.8571.3 5.971.0 4.471.2* 2.6570.7* 5.271.4
a Virus was grown in three different cell types prior to plaque assay in Vero
cells.
b Average plaque sizes (mean diameters7standard deviations) were esti-
mated by counting 20 representative plaques.
c Signiﬁcant difference in plaque size compared to WT virus calculated by
Dunnett’s method of multiple comparisons with an overall type I error of 0.05.
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Fig. 6. Viral RNA:PFU Ratio of prM mutants. Virus was grown in C636 (A), Vero (B),
or COS-1 (C) cells and virus supernatant was harvested on days of peak virus titer.
RNA was extracted and RNA copies/ml was determined by qRT-PCR. Virus titer was
determined by plaque assay. The number of RNA copies/ml was divided by the
virus titer to obtain the ratio of RNA copies/ml to PFU/ml. Asterisks indicate
statistically signiﬁcant differences compared to WT virus using Dunnett’s method
of multiple comparisons with an overall type I error of 0.05. The data shown
are from three independent tests. Plaque assays to determine virus titer were
performed in duplicate, while qRT-PCR experiments were performed in triplicate
for each independent test.
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plaque sizes were reduced in Vero cells compared to WT virus, the
prM mutant viruses were able to overcome deleterious effects
and replicate in all three cell types.
Since the prM mutants did not show signiﬁcant differences
from WT virus growth in all cell culture types we determined the
viral RNA-to-pfu ratio of the mutants to assess the presence of
defective particles and infectious virus compared to WT. Infec-
tious virus titers in cell culture medium were determined when
peak WT titer was achieved (C6/36 and COS-1 cells, day 4; Vero
cells, day 2) by plaque assay, and extracellular RNA in the same
samples was measured by qRT-PCR. The ratio of RNA copies/ml to
PFU/ml for mutant viruses was compared to WT virus in each cell
type and results are shown in Fig. 6. In C6/36 cells there was only
a signiﬁcant difference in the ratio of RNA copies/ml to PFU/ml forthe K31V mutant compared to WT. WT virus produced 1.4 times
more RNA copies/ml than PFU/ml, while the T20D, K31A, K31T
and K31V mutants produced 2.4, 6.3, 7.2 and 15.4 times more
RNA copies/ml than PFU/ml, respectively (Fig. 6A). None of the
mutants had signiﬁcantly higher ratios of RNA copies/ml than
PFU/ml when compared to WT in Vero cells. WT virus produced
22 times more RNA copies/ml than PFU/ml in Vero cells, while
T20D, K31A, K31T and K31V mutants produced 26, 49, 57 and 32
times more RNA copies/ml than PFU/ml, respectively (Fig. 6B). In
COS-1 cells the T20D, K31T and K31V mutants had signiﬁcantly
higher ratios of RNA copies/ml to PFU/ml compared to WT virus.
WT virus produced 15 times more RNA copies/ml than PFU/ml
and T20D, K31A, K31T and K31V produced 236, 29, 45 and 51
times more RNA copies/ml than PFU/ml, respectively (Fig. 6C).
These results indicate that in COS-1 cells, the T20D, K31T and
K31V prM mutations resulted in less efﬁcient production of
infectious virus, and growth of the K31V mutant in C6/36 cells
was less efﬁcient in infectious virus production than WT virus.
Effect of prM mutations on hMAb binding to virions
Previously, the binding of hMAbs to WN VLP epitopes was
characterized, showing that V19 and L33 were key amino
acid residues in the VLP epitope recognized by all three hMAbs
(Calvert et al., 2011). Since the prM mutations (T20D, K31A, K31T
and K31V) prevented secretion of VLP, binding could not be tested
in ELISA. Therefore, these mutations, along with 9 other muta-
tions (V19A, V19N, V19T, T20A, T20Q, T24A, L33A, L33K, L33Q) in
Table 2
Effect of hMAb binding to WNV IC mutant viruses with amino acid substitutions
in pr.
pr AA substitution
in WNV-ICa
Fold change in human Ab titer with pr mutantsb
8G8 5G12 Human serac
WT prM 1.0 1.0 1.0
V19A 2.5 1.7 2.0
V19N 1.5 1.0 1.5
V19T 2.0 1.7 1.5
T20A 3.0 2.0 2.0
T20D 0.1 1.7 1.0
T20Q 1.5 1.3 1.0
T24A 1.3 1.5 1.3
K31A 5.0 2.7 1.2
K31T 2.7 2.0 2.0
K31V 4.0 2.0 2.0
L33A 2.0 2.0 1.3
L33K 2.0 2.0 1.3
L33Q 2.0 1.5 1.3
a Amino acid substitution at speciﬁc residue in the pr portion. Mutants in bold
were previously determined to have a signiﬁcant effect on VLP-hMAb reactivity.
b Four fold reduction or more (bold) in MAb endpoint titer of mutant viruses
compared to WT was considered signiﬁcant.
c Human sera positive for anti-ﬂavivirus antibody was used as control in ELISA
to verify normalized viral protein concentrations.
A.E. Calvert et al. / Virology 433 (2012) 35–4440the pr peptide found to have signiﬁcant effects on hMAb binding,
were incorporated into the WNV infectious cDNA clone (Calvert
et al., 2011). In vitro-transcribed RNA was transfected into C6/36
cells, and virus was harvested 7 days later. Introduced mutations
were conﬁrmed by sequencing of the prM and E genes, and virus
titer was determined by plaque assay. COS-1 cells were infected
with all prM mutant WNVs at an MOI of 0.1 to produce virus for
antigen-capture ELISA to test hMAb binding. COS-1 derived virus
was used in the assay in order to directly compare hMAb binding
to previous results with VLPs secreted from transfected COS-1
cells. Human sera positive for anti-ﬂavivirus antibody was used as
a control in the ELISA to validate that the concentrations of viral
proteins were uniform for all mutant viruses tested. Fold changes
in reactivity with the control sera range from 0 to 2 and indicate
that virus preps used in the ELISA contained comparative con-
centrations of viral proteins.
The only mutations that resulted in a signiﬁcant reduction
in reactivity with hMAb 8G8 were K31A and K31V, with 5- and
4-fold reductions of end-point titers, respectively. The T20D
mutation resulted in a 10-fold increase in reactivity with hMAb
8G8. All other mutations in the pr peptide of WNV resulted in
3-fold or less reduction in hMAb end-point titers, which was not
considered signiﬁcant (Table 2). These results suggest that the
K31 AA residue in virion prM may be important in the binding of
hMAb 8G8.Discussion
Recent research on the functional importance of the prM
protein in ﬂavivirus infections has revealed that the protein is
not only important for viral structure and assembly, but also plays
an important role in infection and immunity. New evidence
shows that non-neutralizing antibodies to prM can enhance DENV
infection of Fc receptor-bearing cells in vitro as well as enhance
WNV infection in vivo (Colpitts et al., 2011; Huang et al., 2008,
2006). These anti-prM antibodies may assist immature virus
particles in cell entry, thereby increasing the number of virus-
producing cells in secondary infections (Dejnirattisai et al., 2010;
Rodenhuis-Zybert et al., 2010). The prM protein of ﬂaviviruses
also plays an important role as a chaperone to the major envelopeglycoprotein E. Not only is the prM protein required for proper
folding and maturation of the E protein during virus assembly, it
also protects the fusion loop on the E protein from premature
fusion before exiting the cell (Konishi and Mason, 1993; Lorenz
et al., 2002; Yu et al., 2009). Recently, the prM protein of DENV
has been shown to associate with members of the ADP-ribosyla-
tion factor (Arf) family of proteins (Kudelko et al., 2012; Wang
et al., 2009). These host cellular factors are known to play a
critical role in intracellular trafﬁcking as well as modulating
membrane curvature, a function critical to the assembly and
budding of ﬂaviviruses from the ER membrane (Beck et al.,
2008; Garoff et al., 1998). The prM protein of DENV was also
shown to interact with vacuolar-ATPases (V-ATPases) in infected
cells. These enzymes acidify intracellular organelles, including
those in the secretory pathway, and pump protons across the
plasma membrane of the cell. This interaction could be signiﬁcant
in both virus entry and membrane fusion via acidiﬁed endosomes
and secretion of newly assembled virus particles out of the cell
(Duan et al., 2008).
In the present study, we describe the effects of 4 speciﬁc
mutations in the WNV prM protein on WN VLP secretion.
Mutations made in prM K31 and T20 in the prM expressed from
the pVAXWN plasmid resulted in a loss of VLP secretion from
transfected COS-1 cells. While K31 mutants were shown to
efﬁciently form prM-E heterodimers, VLP particle secretion was
blocked, resulting in accumulation of viral proteins in the ER,
ER–Golgi intermediary compartments and to some extent in the
Golgi of transfected cells.
Assembly and maturation of viral particles begins at the
membrane of the ER. The prM and E proteins dimerize and then
form an icosahedral scaffold that leads to budding of the envel-
oped particles into the lumen of the ER. These virus particles are
transported through the Golgi and released from the cell via the
exocytic pathway; however, the exact details of this process are
poorly characterized (Mackenzie and Westaway, 2001; Welsch
et al., 2009). Flaviviruses have been shown to associate with
calnexin and calreticulin, lectins found in the ER that assist in the
proper folding of glycoproteins, chaperoning them through the ER
and retaining incompletely folded proteins (Courageot et al.,
2000; Lorenz et al., 2003; Mackenzie and Westaway, 2001; Wu
et al., 2002). Arf proteins have been implicated in DENV VLP
trafﬁcking from the ER to the Golgi since depletion of Arf1, Arf4
and Arf5 resulted in blocking secretion of VLPs and virions
(Kudelko et al., 2012; Wang et al., 2009). In fact, the prM protein
was found to interact with these cellular factors, which may be
crucial in the trafﬁcking and secretion of virus particles through
the cell. While all four DENVs and YFV were shown to produce
less virus when these proteins were down-regulated in the
infected cell, this had no effect on WNV infection and secretion
(Kudelko et al., 2012). This descrepancy may be due to differences
in the two viral particle systems studied, or it may be due to an
inconsistency of the role of these cellular proteins in ﬂavivirus
maturation and secretion.
Interestingly, the epitope containing K31 in the prM protein is
positioned at the top of the prM-E trimer spike in immature virus
particles (Fig. 7A). These mutations had no effect on prM-E
heterodimer formation and protein glycosylation, and appear to
play no role in stabilization of trimer spike formation. Since its
role in virus assembly does not appear to be structurally-related,
we can hypothesize that it must play some role in interacting
with host cellular factors in trafﬁcking the particles through the
ER, Golgi and ultimately out of the cell. L33 was previously
mutated in the WN VLP to an alanine, lysine, glutamine and
threonine and had no effect on VLP secretion (Calvert et al., 2011).
This epitope is not positioned as prominently on the top of the
prM-E trimer spike as K31 (Figs. 7A and B). It is also interesting
Fig. 7. DEN2 prM-E trimer spike at neutral pH (PDB ID: 3C6D): (A) side view of the
viral surface of the DEN2 prM-E trimer spike and (B) top view toward the viral
surface. The E protein is shown in white, while the prM protein is shown in green.
V19 is highlighted in yellow, T20 is highlighted in orange, K31 is highlighted
in red, L33 is highlighted in purple and the glycosylation site (labeled CHO) is
highlighted in cyan.
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conserved residues among ﬂaviviruses, G30 and N32, which
may indicate that this region of prM plays some critical role for
prM structure and function.
The T20D mutation in the prM protein resulted in failure to
form the prM-E heterodimer containing glycosylated prM as
shown by immunoprecipitation studies of lysates from cells
transfected with the mutated plasmid. The T20D mutation caused
inefﬁcient glycosylation of the prM protein, and interestingly only
small amounts of non-glycosylated T20D prM were shown to
associate with the E protein (Fig.2B). The plasmid with T20D
mutation also expressed glycosylated prM in COS-1, but they
were not associated with E protein. Glycosylation of the E protein
of ﬂaviviruses has been studied extensively and shown to be a
critical factor in ﬂavivirus replication, maturation and neuroinva-
siveness in mice (Beasley et al., 2005b; Lad et al., 2000; Li et al.,
2006; Scherret et al., 2001). Glycosylation of the prM protein has
also been shown to be important for heterodimer formation and
secretion of viral proteins from the cell. In JEV, glycosylation of
the prM protein was shown to be an important factor in virion
assembly and release as well as viral pathogenicity in mice (Kim
et al., 2008). Deletion of the prM glycosylation site resulted in a
reduction of secreted TBE and WN VLPs (Goto et al., 2005; Hanna
et al., 2005). The T20 AA residue lies in close proximity to the
glycosylation site on the prM protein in WNV at N15-X16-T17(Fig. 7B). While the mutation does not directly affect the sequence
of the glycosylation site, mutating the small hydrophilic AA
residue threonine to a large negatively charged AA residue
aspartic acid could affect the local biochemistry of the region
which in turn could prevent effective glycosylation of the prM in
the heterodimer structure and/or destabilize heterodimers con-
taining the glycosylated T20D prM. Likewise, each of the prM-E
heterodimers may be affected by the T20 residues in the other
two prM proteins in close proximity in the prM-E trimer spike
(Fig. 7B). Previously, mutations made at this AA residue (A, G, Q)
and those made at AA residue V19 (A, N, R, T) had no effect on VLP
secretion (Calvert et al., 2011).
While these mutations had signiﬁcant effects on VLP secretion,
their effect on virus replication was measurable, but not as
dramatic. K31 mutants replicated reasonably well in the three
cell types tested (C6/36, COS-1 and Vero cells), with a few
exceptions. The K31T mutant replicated more slowly in C6/36
cells than WT or the other prM mutant viruses, while in Vero
cells all the mutants replicated more slowly than WT before
day 2 post-infection. In contrast, K31V was the only mutant to
replicate similarly to WT virus in COS-1 cells. Comparisons of
plaque morphology revealed that all K31 mutants obtained from
any of the three cell types (except for K31V from COS-1 cells)
produced signiﬁcantly smaller plaques than WT viruses in
Vero cells, indicating a replication defect. In comparisons of the
amount of extracellular virus RNA (presumably packaged in
defective particles) to infectious virus particles, the K31V mutant
produced signiﬁcantly higher ratios of RNA to infectious virus
than WT virus in C6/36 and COS-1 cells, while the K31T mutant
only produced signiﬁcantly higher ratios of RNA to infectious
virus than WT virus in COS-1 cells. The T20D mutant also
produced higher ratios of RNA to virus than WT virus in COS-1
cells. While the differences in production of VLP and virus
particles with these mutations are surprising, it is not unprece-
dented. TBE VLP secretion was inhibited by a mutation at prM AA
residue 63 from a proline to a serine; however, when this same
mutation was incorporated into the virus genome, only a 10-fold
decrease in titer over the ﬁrst 48 h of replication was documented
(Yoshii et al., 2004). Likewise, when mutations in JEV ablated
glycosylation of the prM protein, virus particles continued to be
produced, although at a 20-fold decreased titer from WT (Kim
et al., 2008). Taken together, these studies demonstrate that
mutations that affect VLP formation and secretion may not
completely have the same effects on virions. This observation is
important to consider when using VLPs to study virus structure
and function, and signiﬁcant ﬁndings should be conﬁrmed with
replicating virus.
Epitope mapping with hMAbs to the WNVWT and mutant prM
proteins revealed a large disparity between VLP and virion pre-
sentation of the prM protein. This may be due to the relative
concentrations of prM present in the two systems, or to the
presentation of the protein itself and the accessibility of the
epitopes recognized by these hMAbs. Concentrations of VLPs were
standardized by optical density in an ELISA designed to detect all
prM and E proteins in the supernatant. Virions were standardized
by PFU/ml titers, and viral protein concentrations were validated
with the inclusion of polyclonal anti-ﬂavivirus human sera. TBE
VLP which only contains M is the only VLP structure to be solved
of the ﬂaviviruses, therefore it is difﬁcult to compare the unknown
structure of the WN VLP with the resolved structure of the mature
and immature ﬂavivirus particle (Ferlenghi et al., 2001; Kuhn
et al., 2002; Zhang et al., 2003). While differences between virus-
and VLP-expressed E protein do not appear to affect epitope
expression, differences in protein arrangements between VLP,
mature and immature virions could account for differences in
epitope recognition on the prM protein by the hMAbs in our study.
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binding of virions by hMAbs.
This study reiterates the importance of the prM protein in
maturation and assembly of VLP and virions and highlights a
structural region that has not been previously shown to be
important for particle maturation and secretion. The K31 AA
residue in the prM protein of WNV has a signiﬁcant impact on
WNV particle assembly and secretion processes. Further investi-
gation into the speciﬁc role of the prM protein and the critical
epitopes involved will be needed to understand the process of
intracellular trafﬁcking of virus.Materials and methods
Cells
C6/36 (Aedes albopictusmosquito), Vero (African green monkey
kidney) and COS-1 (African green monkey kidney) cells were
cultured as described previously (Davis et al., 2001; Huang et al.,
2000). Cells were maintained in DMEM (Invitrogen) supplemen-
ted with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
110 mg/L sodium pyruvate, 0.1 mM nonessential amino acids,
20 ml/L 7.5% sodium bicarbonate and penicillin (100 U/ml)/strep-
tomycin (100 mg/ml). Vero and COS-1 cells were grown at 37 1C
with 5% CO2 while C6/36 cells were grown at 28 1C with 5% CO2.
Antibodies
The anti-prM MAbs 8G8 and 5G12 (a kind gift from I. Trakht
and G. Kalantarov, Columbia University) are WNV speciﬁc hMAbs
reacting to AA residues V19 and L33 in the prM protein of the VLP
(Calvert et al., 2011). Anti-E MAbs 3.91D and 3.67G were obtained
from the Arbovirus Diagnostic and Reference Collection activity,
DVBD/ADB. These MAbs used in the immunoprecipitation studies
are WNV speciﬁc mMAbs reacting to AA residues S306, K307 and
T332 in DIII of the E protein (David C. Clark, unpublished data).
Site-directed mutagenesis and production of mutant infectious WNV
and WN VLP
The WNV two-plasmid infectious clone (WN-IC) and pVAXWN
plasmid were utilized to produce WNV and VLP respectively, as
previously described (Beasley et al., 2005a; Davis et al., 2001;
Kinney et al., 2006). Site-speciﬁc mutations were introduced into
the prM gene of both systems using the QuikChange site-directed
mutagenesis kit (Stratagene). Mutagenic primer sequences used
for all constructs and transient expression of WN VLP in COS-1
cells by pVAXWN electroporation have been previously described
(Calvert et al., 2011). Electroporated COS-1 cells were recovered
in 6 ml of DMEM supplemented with 10% FCS. Cells were seeded
into 25-cm2 culture ﬂasks for VLP expression and incubated at
37 1C with 5% CO2. Six hours after electroporation, the growth
medium in ﬂasks was replaced with DMEM containing 2% FCS.
Tissue culture medium were harvested 2 and 7 days after
electroporation for determination of VLP secretion by ELISA.
Once full length WN-IC cDNA was obtained, in vitro transcrip-
tion of RNA was carried out as previously described (Kinney et al.,
2006). C6/36 cells were transfected with transcribed RNA by
electroporation. Transfected cells were incubated at 28 1C/5%
CO2 for 7 days at which point supernatant was harvested and
infectious virus titers were determined by plaque assay. The prM
and E genes of WT and mutant viruses were sequenced, and the
correct mutations were found to be present in all mutant viruses
with no compensatory mutations present.Characterization of WN-IC mutant viruses in culture
Viral growth curves were performed in triplicate in 6 well plates of
Vero, COS-1 or C6/36 cells at a MOI of 0.1. After adsorption for 1 h,
maintenance medium containing 2% FCS and penicillin/streptomycin
was added and cultures were incubated in 5% CO2 at 37 1C (Vero and
COS-1 cells) or 28 1C (C636 cells). Aliquots of culture medium were
harvested every day for 7 days, FCS concentration was adjusted to
20% and aliquots were stored at 80 1C prior to titration and RNA
extraction. Viral RNA was extracted from virus supernatant with a
QIAmp Viral RNA kit (Qiagen). WNV-speciﬁc primers to the structural
genes used were based on published data of WNV, strain NY99, and
sequencing was carried out as previously described (Kinney et al.,
2006). Viral RNA was also quantitated at peak viral titers on either
day 2 for Vero or day 4 for COS-1 and C6/36 cells. A 5 ml aliquot of
each sample was added to master mix from iScript One-step RT-PCR
kit (Bio-Rad) containing 200 nM of probe, WN1186F (50–FAM-TGC
CCG ACC ATG GGA GAA GCT C–30), 200 nM of forward primer,
WN1160 (50–TCA GCG ATC TCT CCA CCA AAG–30) and 200 nM of
reverse primer, cWN1229 (50–GGG TCA GCA CGT TTG TCA TTG-30).
WNV-speciﬁc RNA was tested in triplicate and measured by qRT-PCR
using homologous RNA standards on a Bio-Rad IQ5 Real-time PCR
detection system under the following conditions: 50 1C for 30 min,
95 1C for 15min, followed by 45 cycles of 94 1C for 15 s, and 57 1C for
1min with continuous ﬂuorescence data collection. Virus plaque
titrations were performed under double agarose overlay in six-well
plates of conﬂuent Vero cells (Huang et al., 2000). The second agarose
overlay containing neutral red vital stain was added 4 days after
infection, and plaques were counted on day 5 after infection.
Analysis of intracellular mutant VLP proteins
Two days after transfection of COS-1 cells with pVAXWN WT
and mutant plasmids, cells were harvested and cell lysate was
produced as previously described (Blitvich et al., 2003). Similarly,
control antigen was produced with non-transfected COS-1 cells.
Viral proteins were immunoprecipitated from lysates using the
Pierce Immunoprecipitation kit (Thermo Scientiﬁc) with resin
coupled to 75 mg of WNV murine anti-E 3.91D antibody or
75 mg of WNV human anti-prM 8G8 antibody following the
manufacturer’s protocol. Glycosylation patterns of viral proteins
in lysates were analyzed by digestion after immunoprecipitation
using N-glycosidase F (PNGaseF) or Endoglycosidase H (EndoH)
(New England Biolabs) following the manufacturer’s protocol,
before analysis by SDS-PAGE.
SDS-PAGE and immunoblotting
WN viral proteins from immunoprecipitated lysates were
separated by SDS-PAGE on a reduced 4–12% Bis/Tris gel (Invitro-
gen). All procedures were performed at room temperature.
Proteins were blotted electrophoretically from the gels onto
nitrocellulose membranes and washed for 5 min in PBS/0.1%
Tween wash buffer. Non-speciﬁc binding sites were blocked with
1% BSA/PBS for 1 h while rocking. WNV murine anti-E MAb,
3.67 G (10 mg), and puriﬁed rabbit polyclonal sera to WNV prM
(10 mg) (Meridian LifeScience) were incubated with the mem-
brane for 1 h with gentle rocking. Membranes were washed again
in PBS/0.1% Tween wash buffer three times for 5 min each. Goat
anti-mouse antibody and goat anti-rabbit antibody conjugated
to alkaline phosphatase (Jackson Immunoresearch) were diluted
1:200 and incubated on the membrane for 1 h with gentle
rocking. Membranes were washed as described previously and
BCIP/NBT phosphatase substrate (KPL) was added to the mem-
brane until a color change appeared. The reaction was stopped by
the addition of water.
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All ELISAs were performed in 96-well plates (Maxisorp plates,
Nunc). To test for secretion of mutant VLP antigen, rabbit
hyperimmune sera to WNV prM and E proteins was diluted
1:1000 in carbonate/bicarbonate buffer (50 mM sodium carbo-
nate, 50 mM sodium bicarbonate, pH 9.6) and incubated over-
night at 4 1C. Plates were washed ﬁve times with PBS/0.1% Tween
wash buffer with an automatic plate washer. Non-speciﬁc binding
sites were blocked with 3% rabbit serum in PBS (100 ml/well) and
incubated at 37 1C for 1 h. Blocking buffer was removed before
supernatant from transfected COS-1 cells was added to the plate
in doubling dilutions in 3% rabbit serum/PBS (50 ml/well). Antigen
was incubated at 37 1C for 2 h, after which the plates were
washed as previously described. MHIAF to WNV was obtained
from the Reference Collection of the Diagnostic Laboratory, ADB,
DVBID, CDC, and used as the primary antibody at a dilution of
1:1600 in 3% rabbit serum/PBS and incubated at 37 1C for 1 h. Plates
were washed 5 times before the addition of rabbit anti-mouse
antibody conjugated to horseradish peroxidase (50 ml/well), diluted
1:5000 in 3% rabbit serum/PBS. After an incubation period of 1 h at
37 1C, plates were washed again ten times. Enhanced K-blue TMB
substrate (Neogen) was added to each well of the plate (100 ml/well)
and incubated in the dark at room temperature for 10 min. The
reaction was stopped with the addition of 1 N H2SO4 (50 ml/well),
and the plates were read at 450 nm on an automatic plate reader.
To test the reactivity of the mutant viruses with the hMAbs the
protocol remained the same with some exceptions. Viruses were
diluted to a concentration of 106 PFU/ml in 3% rabbit serum/PBS.
Puriﬁed hMAbs were used as the primary antibody and added to
the wells in two-fold dilutions in 3% rabbit serum/PBS (50 ml/
well) starting at 50 mg/ml. The secondary MAb, rabbit anti-human
conjugated to horseradish peroxidase (50 ml/well) was diluted
1:5000 in 3% rabbit serum/PBS. The rest of the ELISA was carried
out as described above.
Immunoﬂuorescence and confocal microscopy
Transfected COS-1 cells were grown on 8-well chamber slides
(Labtek) and incubated in 5% CO2 at 37 1C. 48 h after transfection,
medium was removed and cells were washed 3 times in PBS. Cells
were ﬁxed to the slide with 4% (w/v) paraformaldehyde in PBS for
10 min and permeabilized with 0.1% (v/v) Triton-X 100 in 0.2%
(w/v) BSA/PBS for 10 min. Non-speciﬁc sites were blocked with
10% (v/v) goat serum in PBS for 30 min at 37 1C. Cells were
incubated with WNV murine anti-E antibody 3.91D (5 mg/ml) and
either rabbit anti-calreticulin (1:500), rabbit anti-bCOP1 (1:100),
rabbit anti-ERGIC53 (1:100) or rabbit anti-GRASP65 (1:500)
diluted in PBS for 30 min at 37 1C before being washed 3 times
in PBS. Secondary antibodies, goat anti-mouse conjugated to FITC
and goat anti-rabbit conjugated to Texas Red, were diluted 1:100
in PBS and incubated on the cells for 30 min at 37 1C, and cells
were washed again as previously described. Slides were dried
before the addition of Prolong Gold anti-fade reagent with DAPI
(Invitrogen). Coverslips were mounted on the slides and allowed
to cure at room temperature overnight. Images were viewed and
collected with a Carl Zeiss LSM-Pascal confocal microscope.Acknowledgments
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